Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: AstraZeneca CEO on obesity and more; biotech’s rollercoaster ride set to continue; new Wegovy data; Novo’s plans for semaglutide in NASH; and Zepbound set to become biggest drug ever?
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 17 November 2023, including: AstraZeneca PLC CEO on obesity and more; biotech’s rollercoaster ride set to continue; new Wegovy data; Novo Nordisk A/S’s plans for semaglutide in NASH; and Zepbound set to become biggest drug ever?
This and all our other podcasts are available on the Citeline channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "AstraZeneca CEO Soriot On Obesity, Gene Therapy And More" - Scrip, 13 Nov, 2023.)
(Also see "Jefferies Conference Highlights How Biotech’s Rollercoaster Ride Will Continue Into 2024" - Scrip, 14 Nov, 2023.)
(Also see "AHA 2023 – Wegovy Cuts Death Risk, But Will That Be Enough For Payers?" - Scrip, 11 Nov, 2023.)
(Also see "Novo Nordisk Has Plans For Semaglutide In NASH Too" - Scrip, 15 Nov, 2023.)
(Also see "Lilly’s Zepbound: The Biggest-Selling Drug In The World, Ever?" - Scrip, 15 Nov, 2023.)